Modra Pharmaceuticals Starts Phase 2 Trial of Oral Docetaxel in Metastatic Prostate Cancer June 19, 2017 Modra Pharmaceuticals has enrolled its first patient in a Phase 2 clinical trial (NCT03136640) of ModraDoc006/r as a treatment for metastatic castration-resistant prostate cancer — an advanced and often fatal form of the disease.Read more.Source: Prostate Cancer News Today Prostate Cancer News
Modra Pharmaceuticals has enrolled its first patient in a Phase 2 clinical trial (NCT03136640) of ModraDoc006/r as a treatment for metastatic castration-resistant prostate cancer — an advanced and often fatal form of the disease.Read more.Source: Prostate Cancer News Today
